NCT03411122View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

January 23, 2018

Study Completion Date

January 23, 2018

Conditions
Drug-drug Interactions
Interventions
DRUG

napabucasin

Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.

DRUG

cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate

CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.

Trial Locations (1)

32720

Accel Research Sites, DeLand

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03411122 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers | Biotech Hunter | Biotech Hunter